Matriks Biotek SHIKARI® Q-ATI (semi-quantitative)
Enzyme immunoassay for the semi-quantitative determination of total and free antibodies to infliximab in human serum and plasma.
Infliximab (Remicade) was associated to the development of anti-Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remicade®. This might lead to severe complications. Free and Total Anti drug Antibody monitoring is highly importance along with measuring free drug from samples. Matriks Biotek Shikari Q-ATI semi-quantitative ELISA Kit measures Free and Total anti drug antibodies to Infliximab simultaneously on the same plate.
Total and Free (Semi-Quantitative) Specifications:
|Required Volume (µl)||10|
|Total Time (min)||95|
|Detection Limit (ng/mL)||15|
|Spike Recovery (%)||-|
|Shelf Life (year)||1|
Download IFU (Semi-Quantitative)
Download MSDS (Semi-Quantitative)
Please note that the documentation provided is for reference use only. For the most updated version, please contact us.
For Research Use Only
Manufactured by Matriks Biotek Co.
Questions about this product? Ready to place an order? Email us at email@example.com or give us a call: (650) 486-1541